Mirum Pharmaceuticals Inc - Ordinary Shares
News
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that on September 10, 2024, the Compensation Committee of Mirums Board of Directors granted inducement awards consisting of non-qualified...\n more…
Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue?
Zacks Investment Research It has been about a month since the last earnings report for Mirum Pharmaceuticals, Inc. (MIRM). Shares have added about 4.5% in that time frame, outperforming the S&P 500.Will the recent positive...\n more…
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Recommendation of "Buy" by Analysts
Ticker Report Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) have earned an average rating of "Buy" from the twelve analysts that are covering the firm, MarketBeat Ratings reports. Ten...\n more…
Mirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 12-Month High at $44.99
Ticker Report Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report)'s stock price reached a new 52-week high during trading on Wednesday . The stock traded as high as $44.99 and last traded at $44.99, with a...\n more…
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Bought by Raymond James & Associates
Ticker Report Raymond James Associates lifted its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 10.5% during the second quarter, according to its most recent Form 13F...\n more…
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Business Wire Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and...\n more…